Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the preven
- PDF / 452,366 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 114 Downloads / 196 Views
LETTER
Open Access
Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the HydrOxychloroquine Prophylaxis Evaluation(HOPE) trial: A structured summary of a study protocol for a randomized controlled trial Bharath Kumar Tirupakuzhi Vijayaraghavan1,2* , Vivekanand Jha2,3,4, Dorrilyn Rajbhandari5, Sheila Nainan Myatra6, Oommen John2,7, Arpita Ghosh2,7, Abhinav Bassi2, Sumaiya Arfin2, Mallikarjuna Kunigari2, Rohina Joshi2,8,9, Lachlan Donaldson9,10, Naomi Hammond9,10, Balasubramanian Venkatesh9,11,12 and the HOPE investigators
Abstract Objectives: To evaluate the effect of the combination of hydroxychloroquine (HCQ) and standard personal protective equipment (PPE) compared to the use of standard personal protective equipment alone on the proportion of laboratory confirmed COVID-19 infections among frontline healthcare workers(HCWs) in India Trial design: HOPE is an investigator initiated multi-centre open-label parallel group randomized controlled trial. (Continued on next page)
* Correspondence: [email protected] 1 Department of Critical Care Medicine, Apollo Hospitals, Chennai, India 2 The George Institute for Global Health, New Delhi, India Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Tirupakuzhi Vijayaraghavan et al. Trials
(2020) 21:754
Page 2 of 3
(Continued from previous page)
Participants: All HCWs currently working in an environment with direct exposure to patients with confirmed COVID-19 infection are eligible to participate in the trial. The trial aims to be conducted across 20-30 centres (public and private hospitals) in India. HCWs who decline consent, who have a confirmed COVID-19 infection, those who are already on chloroquine/HCQ for any indication, or if pregnant or breast-feeding, or have known QT prolongation or are on medications that when taken with HCQ can prol
Data Loading...
